前沿速览056期| CAR-T治B淋 前沿览新知
01
CAR-T细胞治疗弥漫大B细胞淋巴瘤——长期获益与真实世界复杂性
Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity
第一作者：Pophali PA
J Clin Oncol (IF=43.4). 2025 Dec 10:JCO2502323.
全文网址：https://ascopubs.org/doi/10.1200/JCO-25-02323?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
大B细胞淋巴瘤患者接受CD19 CAR-T细胞治疗后糖皮质激素的使用模式与安全性
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma
第一作者：Luttwak E
Hemasphere (IF=14.6). 2025 Nov 27;9(11):e70248.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12658336/
03
美国医疗理赔数据库中弥漫大B细胞淋巴瘤患者的真实世界治疗模式与临床结局
Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database
第一作者：Shadman M
Blood Cancer J (IF=11.6). 2025 Dec 5.
全文网址：https://www.nature.com/articles/s41408-025-01412-8
04
CAR-T细胞治疗复发/难治性弥漫大B细胞淋巴瘤结局的微生物组与代谢物生物标志物
Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B cell lymphoma
第一作者：Yoon SE
Blood Adv (IF=7.1). 2025 Dec 9:bloodadvances.2025016858.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016858/557203/Microbiome-and-metabolite-biomarkers-of-CAR-T-cell
05
CAR-T细胞治疗血液系统恶性肿瘤的有效性和安全性：系统综述与荟萃分析的伞状综述
Efficacy and safety of chimeric antigen receptor T-cell in the treatment of hematologic malignancy: an umbrella review of systematic review and meta-analysis
第一作者：Yu Z
Front Immunol (IF=5.9). 2025 Nov 19;16:1608768.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12672455/
06
Lisocabtagene maraleucel在结性和胃肠道滤泡性淋巴瘤中的新作用
Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma
第一作者：Watanabe T
World J Gastroenterol (IF=5.4). 2025 Dec 7;31(45):112336. doi: 10.3748/wjg.v31.i45.112336.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12686993/
07
BY19 (CD19 CAR-T细胞疗法) 治疗白俄罗斯复发/难治性B细胞肿瘤的儿童与成人患者：I期临床试验
CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial
第一作者：Katsin M
Mol Ther Oncol (IF=5.3). 2025 Nov 1;33(4):201081.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12664381/
08
高级别B细胞淋巴瘤：诊断与治疗难度高？
High-grade B-cell lymphomas: high difficulties to diagnose and treat?
第一作者：Davies AJ
Hematology Am Soc Hematol Educ Program (IF=3.2). 2025 Dec 5;2025(1):555-563.
全文网址：https://ashpublications.org/hematology/article-abstract/2025/1/555/556876/High-grade-B-cell-lymphomas-high-difficulties-to?redirectedFrom=fulltext
09
大B细胞淋巴瘤最佳治疗方法的选择与序贯治疗策略的优化
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma
第一作者：Iacoboni G
Hematology Am Soc Hematol Educ Program (IF=3.2). 2025 Dec 5;2025(1):482-488.
全文网址：https://ashpublications.org/hematology/article-abstract/2025/1/482/556841/Selecting-the-best-treatment-approach-and?redirectedFrom=fulltext
10
Tisagenlecleucel治疗复发/难治性B细胞恶性肿瘤的预后因素与结局：一项单中心真实世界研究
Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study
第一作者：Lee SJ
Cytotherapy (IF=3.2). 2025 Nov 17;28(2):102002.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1465-3249(25)00897-7
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.12-16 valid until 2027.12
供稿与审核：临床开发与医学部